| A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) | Geographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Active, not recruiting | Phase 3 | 2026-10-06 | | NCT06510816 |
|---|
| CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME | diabetic macular edema | Active, not recruiting | Phase 3 | 2026-10-02 | | NCT07449923 |
|---|
| A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated | diabetic macular edema | Recruiting | Phase 1 / Phase 2 | 2026-09-30 | | NCT07553429 |
|---|
| A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) | Geographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Recruiting | Phase 2 / Phase 3 | 2026-09-30 | | NCT06635148 |
|---|
| A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME | Diabetic Macular Edema (DME) | Active, not recruiting | Phase 2 / Phase 3 | 2026-09-30 | | NCT06571045 |
|---|
| A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration | Neovascular Age-related Macular Degeneration; nAMD | Recruiting | Phase 3 | 2026-09-29 | | NCT07614776 |
|---|
| A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO | Embolism and Thrombosis, Venous Thrombosis, cardiovascular disorder, eye disorder, retinal disorder, retinal vein occlusion, thrombotic disease, vascular disorder | Recruiting | Phase 2 | 2026-09-04 | | NCT07205887 |
|---|
| A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 | wet macular degeneration | Active, not recruiting | Phase 3 | 2026-09-03 | | NCT06668064 |
|---|
| A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema | diabetic macular edema | Active, not recruiting | Phase 4 | 2026-08-25 | | NCT05224102 |
|---|
| A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME | Diabetic Macular Edema (DME) | Active, not recruiting | Phase 2 / Phase 3 | 2026-08-20 | | NCT06957080 |
|---|
| 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | eye disorder, macular degeneration, retinal degeneration, retinal disorder, wet macular degeneration | Active, not recruiting | Phase 3 | 2026-06-01 | | NCT06864988 |
|---|
| Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration | Neovascular Age-related Macular Degeneration (nAMD) | Active, not recruiting | Phase 1 | 2026-05-01 | | NCT05904691 |
|---|
| A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK | Wet Age-related Macular Degeneration | Active, not recruiting | Phase 3 | 2026-04-29 | | NCT06556368 |
|---|
| Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | eye disorder, macular degeneration, retinal degeneration, retinal disorder, wet macular degeneration | Recruiting | Phase 3 | 2026-04-16 | | NCT07064759 |
|---|
| Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema | Diabetic Macular Edema (DME) | Active, not recruiting | Phase 2 | 2025-10-30 | | NCT06116916 |
|---|
| Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration | Neovascular Age-Related Macular Degeneration (nAMD) | Active, not recruiting | Phase 2 | 2025-10-30 | | NCT06116890 |
|---|
| Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME | diabetic macular edema | Active, not recruiting | Phase 2 | 2025-05-04 | | NCT05387837 |
|---|
| A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration | Neovascular Age-related Macular Degeneration (nAMD) | Not yet recruiting | Phase 3 | 2025-04-06 | | NCT06470373 |
|---|